Results 201 to 210 of about 3,508,804 (299)

Cervical lymph node response to 131I therapy in differentiated thyroid cancer using radiomics and clinical features. [PDF]

Front Oncol
Ruan Y, Yuan H, Zheng F, Chen X, Xu C.
europepmc   +1 more source

Colorectal Cancer Screening in Hereditary and Familial High‐Risk Populations: Best Practices and Future Directions

International Journal of Cancer, EarlyView.
ABSTRACT Colorectal cancer (CRC) remains a leading cause of cancer‐related morbidity and mortality worldwide yet is largely preventable through effective screening and surveillance. While most CRC cases are sporadic, a substantial proportion occur in individuals at increased risk due to hereditary cancer syndromes or family history who require tailored
Ophir Gilad, Francesc Balaguer, Elizabeth E. Half, Kevin J. Monahan, Elena M. Stoffel, Sonia S. Kupfer   +5 more
wiley   +1 more source

Predicting unfavorable response to initial radioactive iodine therapy in differentiated thyroid cancer: an explainable machine learning and survival analysis approach. [PDF]

Front Endocrinol (Lausanne)
Gu L, Zheng G, Zhao Y, Wang J, Qu L, Yao S.   +5 more
europepmc   +1 more source

New‐Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank

International Journal of Cancer, EarlyView.
ABSTRACT The prevalence of type 2 diabetes mellitus (T2DM) is rising rapidly in China and is linked to increased cancer risk, but causality remains unclear due to biases. We examined the causal effect of T2DM on cancer risk using bias‐minimizing methods.
Mengying Wang, Owen Tipping, Bowen Liu, Derrick A. Bennett, Baiyong Shen, Siyi Zou, Shulin Zhao, Richard M. Martin, Matthew Sperrin, Andrew G. Renehan   +9 more
wiley   +1 more source

Effect of social determinants of health care on outcomes for well-differentiated thyroid cancer at an urban safety-net hospital. [PDF]

Thyroid Res
Weldon P, Dunn R, Hoefferle R, Dyer K, Klepacz H, Moncure M, Drees B.   +6 more
europepmc   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

An interpretable nomogram for predicting early acute postoperative hypocalcemia in differentiated thyroid cancer: development and internal validation. [PDF]

Front Endocrinol (Lausanne)
Zhong F, Zhou C, Zhang L, Chen W, Yang Q, Liu D, Zhu Y, Xie L.   +7 more
europepmc   +1 more source

Risk of Developing Subsequent Primary Colorectal Cancers Among Non‐Colorectal Cancer Survivors: Implications for Prevention and Screening

International Journal of Cancer, EarlyView.
ABSTRACT Cancer survivors have an elevated risk of developing subsequent primary cancers, including colorectal cancer (CRC), and may benefit from tailored screening approaches to reduce incidence and morbidity. A retrospective cohort of adults diagnosed with cancer (excluding CRC) in Alberta, Canada from 2000 to 2021 who survived at least 6 months was ...
Dylan E. O'Sullivan, Robert J. Hilsden, Hannah Harsanyi, Matthew T. Warkentin, Kareem Jamani, Huiming Yang, Darren R. Brenner, Safiya Karim, Winson Y. Cheung, Yibing Ruan   +9 more
wiley   +1 more source

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice. [PDF]

Curr Oncol
Ferrari M, Nervo A, Maletta F, Mariani S, Vaccaro E, Piovesan A, Arvat E.   +6 more
europepmc   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source